Showing results (11-20 of 32) with videos related to
Sort By:
Pageof 4
Cancer Reports (Hoboken, N.J.)|March 18, 2026
Identification of BRAF V600E Mutation in Cerebrospinal Fluid Aids in Diagnosing Leptomeningeal Carcinomatosis Arising From Pleomorphic Xanthoastrocytoma: A Case ReportRandy S D'Amico, Patricia Avancena, Alon Kashanian, et al.Clinical Neurology and Neurosurgery|May 7, 2023
Intraoperative awake language mapping correlates to preoperative connectomics imaging: An instructive caseHarshal A Shah, Faina Ablyazova, Annabelle Alrez, et al.Cancers|October 16, 2024
Prioritizing Radiation and Targeted Systemic Therapies in Patients with Resected Brain Metastases from Lung Cancer Primaries with Targetable Mutations: A Report from a Multi-Site Single InstitutionYen-Ruh Wuu, Mostafa Kokabee, Bin Gui, et al.Neuro-Oncology Advances|April 2, 2026
Utility of cerebrospinal fluid circulating tumor cell quantification and next-generation sequencing in patients with suspicion for leptomeningeal diseaseAmanda Onoichenco, Rosivel Galvez, Aaliyah Schultz, et al.The Oncologist|July 22, 2026
Molecular Tumor Board: H3K27M Diffuse Midline Glioma Diagnosed During Pregnancy by Cerebrospinal Fluid Next-Generation SequencingJason Sherman, Thaddeus Harbaugh, Alexander Sisto, et al.NPJ Precision Oncology|August 16, 2025
Clinical and preclinical insights into a novel MDM2::PDGFRA fusion in recurrent glioblastomaCatherine Z Beach, Christopher A Febres-Aldana, Juan Luis Gomez Marti, et al.Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|December 12, 2025
Spinal Rosai-Dorfman disease: systematic review and meta-analysis of clinical presentation, diagnosis, and treatmentAafreen Azmi, Daniela A Perez-Chadid, Jeremiah H Wijaya, et al.Acta Neurochirurgica|December 6, 2025
Intracranial manifestations of adult Rosai-Dorfman disease: a systematic review and IPD meta-analysis of 327 casesDaniela A Perez-Chadid, Aafreen Azmi, Jeremiah H Wijaya, et al.Communications Biology|December 17, 2020
NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitorsRomel Somwar, Nicolle E Hofmann, Bryan Smith, et al.Journal of Neuro-Oncology|May 16, 2026
Should checkpoint inhibitors be reserved for biomarker-selected pediatric brain tumors?Yaxel Levin-Carrion, Jayant Bhasin, Kevin Titkov, et al.Pageof 4